SCHEMBL6543516

SCHEMBL6543516

CC(c1ccc2ccccc2c1)N(C)c1ccccc1

nearest known ligand 0.54

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.53
SLC6A2 P23975 4/20 0.46
SLC6A4 P31645 4/20 0.46
SLC6A3 Q01959 4/20 0.46
KCNH2 Q12809 2/20 0.46
CYP2D6 P10635 2/20 0.46
CYP3A4 P08684 1/20 0.46
AOC3 Q16853 2/20 0.46
ADRA2A P08913 2/20 0.45
ADRA2B P18089 2/20 0.45
ADRA2C P18825 2/20 0.45
KDM4E B2RXH2 1/20 0.43
MEN1 O00255 2/20 0.42
KMT2A Q03164 2/20 0.42
CYP1A2 P05177 1/20 0.42
TSHR P16473 1/20 0.42
HIF1A Q16665 1/20 0.42
ATM Q13315 1/20 0.42
TPH1 P17752 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8439038 0.82 UGT2B7 (0.59) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL14475276 0.82 UGT2B7 (0.59) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL5075640 0.81 KDM4E (0.52) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL5962501 0.81 UGT2B7 (0.57) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL6034044 0.81 UGT2B7 (0.57) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
SCHEMBL31175221 0.80 SLC6A2 (0.47) SLC6A2SLC6A4CYP2D6AOC3KDM4E
SCHEMBL2232118 0.80 SLC6A2 (0.47) SLC6A2SLC6A4CYP2D6AOC3KDM4E
SCHEMBL19008845 0.77 NR3C2 (0.41) SLC6A2SLC6A4MEN1KMT2A
SCHEMBL19737790 0.76 UGT2B7 (0.52) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2
Hydrogen Peroxide SCHEMBL8096014 0.76 UGT2B7 (0.72) UGT2B7SLC6A2SLC6A4SLC6A3KCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1259475-A4 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS UNIV YALE (US) 2004-08-18 EP disclosed
EP-1259475-A1 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS YALE UNIVERSITY (US) 2002-11-27 EP disclosed
US-6384282-B2 CATALYST IS REACTION PRODUCT OF GROUP 8 METAL AND LIGAND YALE UNIVERSITY 2002-05-07 US disclosed
US-20020016509-A1 Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds YALE UNIVERSITY 2002-02-07 US disclosed
WO-2001064620-A1 TRANSITION METAL-CATALYZED PROCESS FOR ADDITION OF AMINES TO CARBON-CARBON DOUBLE BONDS YALE UNIVERSITY (US) 2001-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020016509-A1 Transition metal-catalyzed process for addition of amines to carbon-carbon double bonds COASY, CMA1, ATIC UGT2B7 912/4885SLC6A2 358/4885SLC6A4 502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.